Trade Report: Today: Edwards Lifesciences Corp. (EW) Stake Raised by Sentry Investment Management LLC

Today: Edwards Lifesciences Corp. (EW) Stake Raised by Sentry Investment Management LLC

Sentry Investment Management LLC boosted its stake in Edwards Lifesciences Corp. (NYSE:EW) by 8.9% during the third quarter, Holdings Channel reports. The fund owned 14,058 shares of the medical research company’s stock after buying an additional 1,150 shares during the period. Sentry Investment Management LLC’s holdings in Edwards Lifesciences Corp. were worth $1,695,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Columbus Circle Investors raised its position in Edwards Lifesciences Corp. by 1.6% in the second quarter. Columbus Circle Investors now owns 2,209,825 shares of the medical research company’s stock valued at $220,386,000 after buying an additional 33,790 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of Edwards Lifesciences Corp. by 74.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 97,852 shares of the medical research company’s stock worth $11,797,000 after buying an additional 41,853 shares during the last quarter. Capital Fund Management S.A. raised its position in shares of Edwards Lifesciences Corp. by 10,543.8% in the second quarter. Capital Fund Management S.A. now owns 473,012 shares of the medical research company’s stock worth $47,173,000 after buying an additional 468,568 shares during the last quarter. Frontier Capital Management Co. LLC raised its position in shares of Edwards Lifesciences Corp. by 102.0% in the second quarter. Frontier Capital Management Co. LLC now owns 610,357 shares of the medical research company’s stock worth $60,871,000 after buying an additional 308,223 shares during the last quarter. Finally, Dorsey Wright & Associates raised its position in shares of Edwards Lifesciences Corp. by 5.9% in the third quarter. Dorsey Wright & Associates now owns 42,400 shares of the medical research company’s stock worth $5,112,000 after buying an additional 2,369 shares during the last quarter. 83.08% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Corp. (NYSE:EW) traded down 1.4241% on Monday, hitting $84.5781. 1,404,503 shares of the stock were exchanged. The firm has a market cap of $18.08 billion, a PE ratio of 33.4301 and a beta of 0.71. Edwards Lifesciences Corp. has a 52-week low of $72.20 and a 52-week high of $121.75. The company has a 50-day moving average price of $100.51 and a 200-day moving average price of $106.69.

Edwards Lifesciences Corp. (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 earnings per share for the quarter, hitting the consensus estimate of $0.68. Edwards Lifesciences Corp. had a return on equity of 24.32% and a net margin of 19.24%. The company earned $739.40 million during the quarter, compared to analyst estimates of $749.14 million. During the same quarter last year, the firm posted $0.54 EPS. The firm’s revenue for the quarter was up 20.1% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Corp. will post $2.88 EPS for the current fiscal year.

EW has been the topic of a number of research reports. Zacks Investment Research lowered shares of Edwards Lifesciences Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Canaccord Genuity reaffirmed a “buy” rating and issued a $140.00 price target on shares of Edwards Lifesciences Corp. in a research note on Thursday, August 18th. Evercore ISI reaffirmed a “hold” rating and issued a $115.00 price target on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Credit Suisse Group AG set a $116.00 price target on shares of Edwards Lifesciences Corp. and gave the company a “buy” rating in a research note on Thursday, August 18th. Finally, Morgan Stanley reaffirmed a “buy” rating and issued a $140.00 price target on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $117.68.

In other Edwards Lifesciences Corp. news, CEO Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp. stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of $92.77, for a total transaction of $4,555,007.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Larry L. Wood sold 13,257 shares of Edwards Lifesciences Corp. stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $119.27, for a total value of $1,581,162.39. The disclosure for this sale can be found here. 2.37% of the stock is owned by corporate insiders.

Edwards Lifesciences Corp. Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Related posts

Leave a Comment